Lilly Announces Agreement to Acquire Dermira

Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis Acquisition also includes QBRE... Biopharmaceuticals, Dermatology, Mergers & Acquisitions Eli Lilly, Dermira , lebrikizumab, atopic dermatitis, QBREXZA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news